A nanoagonist based on bovine serum albumin (BSA)/ferritin combined with manganese (II) and β-lapachone has been shown to target the tumour microenvironment (TME) and dissociate to release Mn2+, which targets DC cells, to enhance the dsDNA binding capacity of cGAS, and β-lapachone, which targets tumour cells to induce apoptosis, thus initiating signalling cascades that increase local antitumour effects 47. Here, CGAS is linked to neoplasm.